VYXEOS
Total Payments
$140.3M
Transactions
10,762
Doctors
2,835
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.4M | 662 | 169 |
| 2023 | $1.9M | 778 | 296 |
| 2022 | $40.0M | 1,168 | 289 |
| 2021 | $37.7M | 1,177 | 337 |
| 2020 | $35.3M | 1,255 | 474 |
| 2019 | $15.2M | 3,072 | 1,214 |
| 2018 | $5.2M | 1,825 | 778 |
| 2017 | $546,668 | 825 | 298 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $134.8M | 2,413 | 96.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.5M | 769 | 1.8% |
| Consulting Fee | $1.3M | 410 | 0.9% |
| Grant | $870,450 | 18 | 0.6% |
| Travel and Lodging | $509,651 | 1,471 | 0.4% |
| Food and Beverage | $261,145 | 5,554 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $127,850 | 42 | 0.1% |
| Honoraria | $5,026 | 2 | 0.0% |
| Education | $2,086 | 82 | 0.0% |
| Gift | $20.92 | 1 | 0.0% |
Payments by Type
Research
$134.8M
2,413 transactions
General
$5.6M
8,349 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED AML WITH OR WITHOUT FLT3 MUTATIONS | JAZZ PHARMACEUTICALS INC. | $29.4M | 0 |
| A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO TO CPX351 WITH GO | JAZZ PHARMACEUTICALS INC. | $28.7M | 0 |
| CLINICAL CPX-351 INVESTIGATOR SPONSORED TRIALS | JAZZ PHARMACEUTICALS INC. | $10.6M | 0 |
| MD ANDERSON CANCER CENTER COLLABORATIVE STUDY | JAZZ PHARMACEUTICALS INC. | $4.0M | 0 |
| SIV-JAZZ PHARMACEUTICALS STRATEGIC ALLIANCE AGREEMENT | JAZZ PHARMACEUTICALS INC. | $4.0M | 0 |
| V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATE CPX-351 COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | JAZZ PHARMACEUTICALS INC. | $4.0M | 0 |
| A PHASE 1 TRIAL TO EVALUATE THE POTENTIAL IMPACT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF CPX-351 (DAUNORUBICIN AND CYTARABINE) LIPOSOME FOR INJECTION TREATMENT IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES (CPX351-102) | JAZZ PHARMACEUTICALS INC. | $3.0M | 0 |
| A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations | JAZZ PHARMACEUTICALS INC. | $2.9M | 0 |
| A PHASE 1B TRIAL OF CPX-351 LOWER INTENSITY THERAPY (LIT) PLUS VENETOCLAX AS FIRST LINE TREATMENT FOR SUBJECTS WITH AML WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY | JAZZ PHARMACEUTICALS INC. | $2.9M | 0 |
| V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATECPX-351 COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | JAZZ PHARMACEUTICALS INC. | $2.7M | 0 |
| PHASE I/II TRIAL OF CPX-351 + PALBOCICLIB IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | JAZZ PHARMACEUTICALS INC. | $1.9M | 0 |
| A PHASE 1 TRIAL TO EVALUATE THE POTENTIAL IMPACT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF CPX -351 (DAUNORUBICIN AND CYTARABINE) LIPOSOME FOR INJECTION TREATMENT IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES | JAZZ PHARMACEUTICALS INC. | $1.8M | 0 |
| A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED AML WITH OR WITHOUT FLT3 MUTATIONS | Jazz Pharmaceuticals Inc. | $1.3M | 0 |
| A PILOT STUDY OF CPX-351 (VYXEOS) FOR TRANSPLANT ELIGIBLE, HIGHER RISK PATIENTS WITH MYELODYSPLASTIC SYNDROME | JAZZ PHARMACEUTICALS INC. | $1.2M | 0 |
| Phase II Trial OF CPX-351 CYTARABINEDAUNORUBICIN Liposome Injection Alone in Patients with Acute Myeloid Leukemia 60 Years of Age Who Have Not Been Treated with Intensive Chemotherapy | Jazz Pharmaceuticals Inc. | $1.2M | 0 |
| A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX 351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED AML WITH OR WITHOUT FLT3 MUTATIONS | JAZZ PHARMACEUTICALS INC. | $1.1M | 0 |
| A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) | JAZZ PHARMACEUTICALS INC. | $1.0M | 0 |
| LIPOSOME-ENCAPSULATED DAUNORUBICIN-CYTARABINE AND GEMTUZUMAB OZOGAMICIN IN TREATING PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR HIGH RISK MYELODYSPLASTIC SYNDROME | JAZZ PHARMACEUTICALS INC. | $1.0M | 0 |
| PHASE II STUDY OF CPX-351 IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) | JAZZ PHARMACEUTICALS INC. | $996,461 | 0 |
| LOWER DOSES OF CPX-351 AS A NOVEL APPROACH FOR THE TREATMENT OF OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | JAZZ PHARMACEUTICALS INC. | $988,037 | 0 |
Top Doctors Receiving Payments for VYXEOS — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology | New York, NY | $19,412 | 10 |
| , M.D | Hematology & Oncology | Dyer, IN | $18,478 | 25 |
| , MD, PHD | Medical Oncology | Boston, MA | $17,130 | 15 |
| , MD | Pediatrics | Philadelphia, PA | $16,918 | 2 |
| , M.D | Hematology & Oncology | Tampa, FL | $16,167 | 18 |
| , MD | Hematology & Oncology | Tampa, FL | $15,383 | 8 |
| , MD | Hematology & Oncology | Stanford, CA | $15,306 | 19 |
| Daniel Arber | Anatomic Pathology & Clinical Pathology | Willowbrook, IL | $15,174 | 14 |
| , MD | Hematology & Oncology | Tampa, FL | $15,045 | 21 |
| , M.D | Hematology | Washington, DC | $14,527 | 39 |
| , M.D | Internal Medicine | Houston, TX | $14,233 | 21 |
| , MD PHD | Hematology | Seattle, WA | $14,207 | 12 |
| , MD | Hematology | Tampa, FL | $13,984 | 9 |
| , M.D | Internal Medicine | Milwaukee, WI | $12,829 | 12 |
| , MD | Medical Oncology | Philadelphia, PA | $12,820 | 5 |
| , MD | Hematology & Oncology | New York, NY | $12,751 | 7 |
| , M.D | Hematology & Oncology | Houston, TX | $12,655 | 18 |
| , M.D | Internal Medicine | Columbus, OH | $12,655 | 15 |
| , M.D | Internal Medicine | Baltimore, MD | $12,566 | 4 |
| , M.D | Diagnostic Radiology | Dallas, TX | $11,006 | 9 |
| , MD | Hematology | Boston, MA | $10,692 | 11 |
| , M.D | Medical Oncology | Solvang, CA | $10,580 | 7 |
| , MD | Hematology & Oncology | Birmingham, AL | $9,715 | 20 |
| , MSN, NP-C | Family | Birmingham, AL | $9,503 | 19 |
| , M.D., PH.D | Hematology | Hawthorne, NY | $9,384 | 18 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $130.2M
- Jazz Pharmaceuticals Inc. $10.1M
- Nippon Shinyaku Co.,Ltd $21,488
Product Information
- Type Drug
- Total Payments $140.3M
- Total Doctors 2,835
- Transactions 10,762
About VYXEOS
VYXEOS is a drug associated with $140.3M in payments to 2,835 healthcare providers, recorded across 10,762 transactions in the CMS Open Payments database. The primary manufacturer is Jazz Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $4.4M was paid across 662 transactions to 169 doctors.
The most common payment nature for VYXEOS is "Unspecified" ($134.8M, 96.0% of total).
VYXEOS is associated with 20 research studies, including "A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED AML WITH OR WITHOUT FLT3 MUTATIONS" ($29.4M).